Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 7:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 5,903 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 3 Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Home Health and Air Pollution Study

NCT06030336
View directory record Official record
Conditions
Indoor Air Quality
Interventions
Home Health Report
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 27, 2026, 7:30 AM EDT
Active, not recruiting Phase 1 Interventional

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

NCT06177171
View directory record Official record
Conditions
BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation
Interventions
Olaparib, ASTX727
Drug
Lead sponsor
Varun Monga, MBBS
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 27, 2026, 7:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Tailored-Motivational Interviewing Project

NCT03181022
View directory record Official record
Conditions
HIV
Interventions
Motivational Interviewing
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Detroit, Michigan • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 27, 2026, 7:30 AM EDT
Not listed Not applicable Interventional

VIA Disc Nucleus Pulposus Older Patients Pilot

NCT05412277
View directory record Official record
Conditions
Degenerative Disc Disease, Low Back Pain, Disc Degeneration
Interventions
VIA Disc Nucleus Pulposus Allograft
Other
Lead sponsor
VIVEX Biologics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Tampa, Florida • Newnan, Georgia • Slidell, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 27, 2026, 7:30 AM EDT
Active, not recruiting Phase 1 Interventional

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

NCT04141644
View directory record Official record
Conditions
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
Interventions
Ipilimumab, Osimertinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 27, 2026, 7:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)

NCT01100931
View directory record Official record
Conditions
NSCLC, Solid Tumors
Interventions
YM155, Carboplatin, Paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 27, 2026, 7:30 AM EDT
Terminated Phase 4 Interventional Results available

Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing

NCT02749292
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 82 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 27, 2026, 7:30 AM EDT
Active, not recruiting Not applicable Interventional

Expanding Live Donor Kidney Transplantation Through Advocacy Training and Social Media

NCT03099434
View directory record Official record
Conditions
Kidney Failure, Kidney Diseases
Interventions
Facebook App, Live Donor Champion + Facebook App
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Evanston, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 27, 2026, 7:30 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers

NCT04204772
View directory record Official record
Conditions
Healthy Adult Volunteers
Interventions
Activated charcoal and Tap Water, Activated Charcoal and Apple Juice
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 27, 2026, 7:30 AM EDT
Completed Phase 1 Interventional

A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period

NCT03414736
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR425899
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 27, 2026, 7:30 AM EDT
Completed Phase 1 Interventional

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

NCT01965353
View directory record Official record
Conditions
Multiple Myeloma in Relapse
Interventions
Panobinostat, Dexamethasone, Lenalidomide, Bortezomib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 27, 2026, 7:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

NCT00141037
View directory record Official record
Conditions
Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
Interventions
Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 27, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants

NCT06177457
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07293893, Placebo, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 27, 2026, 7:30 AM EDT
Completed Phase 2 Interventional Results available

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

NCT03045328
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Venetoclax
Drug
Lead sponsor
Steven E. Coutre
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Duarte, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 27, 2026, 7:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults

NCT05923411
View directory record Official record
Conditions
Healthy Participants
Interventions
Single dose of PF-07220060 as first Tablet Formulation, Single dose of PF-07220060 as second Tablet Formulation, Single dose of PF-07220060 as a Tablet Formulation, Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration, Single dose of PF-07220060 as third tablet formulation
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 27, 2026, 7:30 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Does Testosterone Therapy Improve Patient-Reported Outcomes in Age-Related Testosterone Deficient Patients Undergoing Total Hip Replacement: A Randomized-Controlled Trial

NCT05722301
View directory record Official record
Conditions
Arthroplasty, Replacement, Hip
Interventions
Testosterone Therapy, No Testosterone Therapy
Drug · Other
Lead sponsor
American Hip Institute
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Des Plaines, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 27, 2026, 7:30 AM EDT
Active, not recruiting Phase 1 Interventional

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

NCT04464200
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Burkitt's Lymphoma, Primary CNS Lymphoma
Interventions
19(T2)28z1xx CAR T cells
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 27, 2026, 7:30 AM EDT
Recruiting Phase 1 Interventional

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

NCT04903119
View directory record Official record
Conditions
Metastatic Melanoma, BRAF Gene Mutation
Interventions
Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg, Nilotinib 400mg, Dabrafenib, Trametinib, Encorafenib, Binimetinib
Drug
Lead sponsor
Rina Plattner
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
4
States / cities
Iowa City, Iowa • Lexington, Kentucky • Easton, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 27, 2026, 7:30 AM EDT
Recruiting Not applicable Interventional

Brief Interventions to Reduce Comorbid Alcohol and Cannabis Misuse and Sleep Impairment in Young Adults (Rest-Up RCT)

NCT06736444
View directory record Official record
Conditions
Insomnia, Alcohol Use, Marijuana Use
Interventions
Brief Behavioral Therapy for Insomnia (BBTI), Brief Alcohol Screening and Intervention for College Students (BASICS), Attention Control
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 29 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 27, 2026, 7:30 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall

NCT00826085
View directory record Official record
Conditions
Breast Cancer
Interventions
ThermoDox in combination with Microwave Hyperthermia (heat)
Drug
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
San Francisco, California • Newnan, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 27, 2026, 7:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Coordination of Care Between Pediatricians and Women Infants & Children Nutritionists

NCT03482908
View directory record Official record
Conditions
Childhood Obesity
Interventions
Early healthy lifestyles, Responsive parenting curriculum, Data sharing/coordination
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 55 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 27, 2026, 7:30 AM EDT
Recruiting Phase 1 Interventional

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

NCT05210374
View directory record Official record
Conditions
Relapsed Sarcomas
Interventions
Disulfiram, Copper Gluconate, Liposomal Doxorubicin (Doxil)
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 27, 2026, 7:30 AM EDT
Terminated Phase 1 Interventional Results available

CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

NCT00702923
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide and CP-675,206 (Tremelimumab), Bicalutamide, CP-675,206 (Tremelimumab), Bicalutamide, CP-675,206
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 27, 2026, 7:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluate Pharmacokinetics and Safety of Slow Release DHEA

NCT05623059
View directory record Official record
Conditions
Asthma, Genotype
Interventions
Slow Release DHEA
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 7:30 AM EDT